Skip to main content
Vitamin D might not be much help for strengthening bones among healthy adults without osteoporosis, Canadian researchers reported, even at doses far higher than recommended daily allowances. In a clinical trial assessing three levels of daily vitamin D supplementation -- 400 IU, 4,000 IU, and 10,000 IU -- radial volumetric bone mineral density was significantly lower among those (ages 55-70) taking higher doses for 3 years, according to Steven
FDA grants breakthrough status to OFEV (nintedanib) forthe treatment of chronic fibrosing interstitial lung diseases (ILDs), other than idiopathic pul

Dr. John Cush RheumNow

7 years 1 month ago

FDA grants breakthrough status to OFEV (nintedanib) forthe treatment of chronic fibrosing interstitial lung diseases (ILDs), other than idiopathic pulmonary fibrosis (which it is currently approved for). Nintedanib has been studied in PSS ILD. https://t.co/K0ZTyqrfh6

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.
The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  The recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.  The updated package insert can be found here.
The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).
FDA has approved Taltz (ixekizumab) use in Active Ankylosing Spondylitis (Axial Spondyloarthritis). IXE previously approved for psoriasis & PsA.

Dr. John Cush RheumNow

7 years 1 month ago
FDA has approved Taltz (ixekizumab) use in Active Ankylosing Spondylitis (Axial Spondyloarthritis). IXE previously approved for psoriasis & PsA. Recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. https://t.co/S8zwuYuK2H
@ClinRheumatol Whoa...this an 11 patient uncontrolled report - not a study and certainly NOT evidence that abatacept works in Sjogrens. ABA is not inc

Dr. John Cush RheumNow

7 years 1 month ago
@ClinRheumatol Whoa...this an 11 patient uncontrolled report - not a study and certainly NOT evidence that abatacept works in Sjogrens. ABA is not included in guidelines for, and not approved for use in Sjogrens. Journals who promote$$$ their publications should not be interpreting results!
European Study of 24,195 axSpA pts shows that 1st TNFi resulted in 27% ASDAS inactive disease @6 months & 59% achieved BASDAI <40; 80% continue

Dr. John Cush RheumNow

7 years 1 month ago
European Study of 24,195 axSpA pts shows that 1st TNFi resulted in 27% ASDAS inactive disease @6 months & 59% achieved BASDAI <40; 80% continued Rx after 1 year. 1178 patients w/ non-radiographic axSpA had lower 12-mos retention (73%) https://t.co/KJn5eD6wWw
https://t.co/Es3nquURHJ is my new website for Physicians and Patients interested in Still’s disease (systemic juvenile idiopathic arthritis), period

Dr. John Cush RheumNow

7 years 1 month ago
https://t.co/Es3nquURHJ is my new website for Physicians and Patients interested in Still’s disease (systemic juvenile idiopathic arthritis), periodic fever syndromes and autoinflammatory diseases. Check out the cool AOSD Diagnosis Calculator!
Day 2 of the NIH Symposium on Autoinflammatory and immune-dysregulatory Diseases - 90 World experts on IL-1 mediated autoinflammatory diseases, autoin

Dr. John Cush RheumNow

7 years 1 month ago
Day 2 of the NIH Symposium on Autoinflammatory and immune-dysregulatory Diseases - 90 World experts on IL-1 mediated autoinflammatory diseases, autoinflammatory Type-I interferonopathies, MAS/HLH, LIVE STREAMING here>> https://t.co/WQjtS1JJue
Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.
×